Hikal per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−₹2.74−₹3.96₹7.36₹5.64₹6.36
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−₹2.74−₹3.96₹7.36₹5.64₹6.36
₹97.07₹97.07₹102.21₹96.32₹91.93
₹140.49₹138.67₹150.59₹144.74₹164.07
—₹24.45₹22.70₹15.14₹25.57
₹12.46₹12.46₹11.59−₹1.42₹1.03
—₹1.00₹1.20₹1.20₹1.00
12.412.412.412.312.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

HIKAL₹202.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,496 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS6.365.647.36-3.96-2.74
Diluted EPS6.365.647.36-3.96-2.74
Book Value per Share91.9396.32102.2197.0797.07
Revenue per Share164.07144.74150.59138.67140.49
Cash Flow per Share25.5715.1422.7024.45—
Free Cash Flow per Share1.03-1.4211.5912.4612.46
Dividends per Share1.001.201.201.00—
Shares Outstanding (cr)12.312.312.412.412.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.